Consistent with other findings linking MET and EGFR oncogenic signaling, the resistance to MET inhibitors in lung and stomach carcinoma cells was accounted by NRP1-dependent EGFR upregulation [36]. This evidence concerns the gene MET and gastric carcinoma.